Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

[1]  B. Thapa,et al.  Immunotherapy for malignant mesothelioma: reality check , 2016, Expert review of anticancer therapy.

[2]  Manish R. Patel,et al.  Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. , 2016 .

[3]  B. Milleron,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[4]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.

[5]  J. Larkin,et al.  Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.

[6]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[7]  A. Ribas,et al.  Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. , 2015, European journal of cancer.

[8]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.

[9]  M. Maio,et al.  Immune checkpoint blockade in malignant mesothelioma. , 2015, Seminars in oncology.

[10]  M. Maio,et al.  Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy , 2015, Vaccines.

[11]  J. Beebe-Dimmer,et al.  Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival , 2015, Clinical epidemiology.

[12]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[13]  M. Maio,et al.  Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. , 2015, The Lancet. Respiratory medicine.

[14]  L. Camacho.  CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations , 2015, Cancer medicine.

[15]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Wolchok,et al.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. , 2014, Cancer treatment reviews.

[17]  M. Maio,et al.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.

[18]  J. Wolchok,et al.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[21]  Eun‐Kee Park,et al.  Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. , 2011, Bulletin of the World Health Organization.

[22]  M. Sadelain,et al.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma , 2011, Cancer Immunology, Immunotherapy.

[23]  A. Tsao,et al.  VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial , 2011 .

[24]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[25]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[27]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[28]  O. Guilbaud,et al.  A recycling framework for the construction of Bonferroni‐based multiple tests , 2009, Statistics in medicine.

[29]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  John P Klein,et al.  Analyzing survival curves at a fixed point in time , 2007, Statistics in medicine.

[31]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[32]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[35]  G. Ceresoli,et al.  CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? , 2014, Cancer Immunology, Immunotherapy.

[36]  F. Thistlethwaite,et al.  Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. , 2011, Clinical immunology.

[37]  F. Ricceri,et al.  Survival of pleural malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[39]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.